Streetwise Reports' Article Archives — September 2018 back to current month (14)
With this development, the Canadian firm entered a new geography and an additional market segment.
This regenerative medicine company moves one step closer to commercialization of its cell therapies in East Asia.
A Maxim Group analyst reported on news and upcoming catalysts for this late-stage drug developer.
An H.C. Wainwright & Co. report reviewed both the results and an "unusual" highlight from this firm's trial in head-and-neck cancer.
This is the second large shipment to the Philippine distributor.
Tilray's wild fluctuations have grabbed the headlines the past few days, but Fincom Investment Partners profiles a rapidly emerging player in the cannabis realm that the firm believes has much more to offer.
An H.C. Wainwright & Co. report outlined the investment thesis for this U.S.-based biopharmaceutical firm.
A Mackie Research Capital report tells how this biotech will benefit from its new and existing programs with this specific partner.
Permission has been obtained to distribute time-release capsules.
With CAR-T being the hottest space in cancer therapy, Daniel Carlson of Tailwinds Research profiles an innovative company that has been collaborating with a major cancer center.
An Echelon Wealth Partners report discussed the deal terms.
A ROTH Capital Partners note explained the outcome of the tÍte-a-tÍte and its implications.
A Ladenburg Thalmann report covered the asset, product market and financial projections of this Florida-based company.
A ROTH Capital Partners report provided the takeaways from a recent meeting with the management team for this company, which is targeting an orphan indication.
|"DRRX's psoriasis trial is on target for topline data by year-end 2019."|